Objective To evaluate the efficacy and safety of ferric derisomaltose in the treatment of iron deficiency anemia associated with abnormal uterine bleeding (AUB).

Methods The data of sixty-four patients with iron deficiency anemia caused by AUB were retrospectively analyzed. According to the use of anti-anemia drugs, the patients were divided into ferric derisomaltose group (n=21), oral iron supplementation group (n=20) and iron sucrose group (n=23). The iron isomaltose group was treated with iron isomaltose injection, the oral iron prescription group was treated with iron protein succinate oral solution or ferrous succinate tablet, and the iron sucrose group was treated with iron sucrose injection. The changes of hemoglobin (Hb) and serum ferritin (SF) were observed at baseline and at the 3rd day, 4th and 12th week of treatment. The incidences of common adverse events, such as allergic reactions and gastrointestinal reactions during treated by iron isomaltose, oral iron supplementation and iron sucrose were compared.

Results At the 4th and 12th week of treatment, Hb levels in the ferric derisomaltose group was higher than those of the oral iron supplementation group and iron sucrose group (P < 0.05). The incidence of adverse events was the lowest in the ferric derisomaltose group and the highest in the oral iron group. The main adverse events in the ferric derisomaltose group were infusion-related adverse reactions, which were mild and did not require additional treatment, and had no effect on compliance.

Conclusion For patients with anemia caused by uterine hemorrhage, treatment with ferric derisomaltose could result in increase of Hb and SF, and this beneficial effect can last for at least 12 weeks with low incidence of adverse reaction and good tolerance.